← Leaderboards
Timothy Cooley
Boston University Medical Campus
$10,286
Attributed
$10,286
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$10,286 · 4
By mechanism
M01$10,286 · 4
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Jeffrey H Samet$129,777,857
- H Scott Swartzwelder$9,953,856
- Stephen I. Pelton$1,352,372
- Susan P Perrine$12,101,972
- George T O'Connor$16,562,962
Others in their field
Top investigators on “Aids Therapy”
- Lawrence Corey · Fred Hutchinson Cancer Center$356,191,804
- Constance Ann Benson · University Of California, San Diego$277,003,036
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,875,323
- Barbara Driver · Westat, Inc.$205,980,213
- Sharon A Nachman · Johns Hopkins University$193,704,208
- Carol Nesel · Westat$188,148,170
Research focus
Aids TherapyClinical ResearchHuman SubjectHuman Therapy EvaluationHiv InfectionsAntiaids AgentClinical Trial Phase IDrug Administration Rate /DurationDrug Screening /EvaluationPharmacokineticsTetracyclinesEfavirenzAntineoplasticsHuman Immunodeficiency Virus 1Angiogenesis InhibitorsAlpha BenzopyroneKaposi'S SarcomaNeoplasm /Cancer ChemotherapyVirus LoadPlant ExtractsProtease InhibitorAntiviral AgentsReverse Transcriptase InhibitorsCombination Chemotherapy
Grant awards (7)
METFORMIN AND ROSIGLITAZONE IN HIV-INFECTED PATIENTS$4,168
M01 · FY2005 · RR
INITIAL THERAPY FOR HIV-I INFECTION (ACTG A5142)$2,500
M01 · FY2005 · RR
INITIAL THERAPY FOR HIV-I INFECTION (ACTG A5142)$3,618
M01 · FY2004 · RR
EFFECTS OF (+) - CALANOLIDE A ON SURROGATE MARKERS IN HIV POSITIVE PATIENTS$0
M01 · FY2001 · RR
(AMC 011) PHASE I STUDY OF COL 3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2001 · RR
EFFECTS OF CALANOLIDE A ON SURROGATE MARKERS IN HIV POSITIVE PATIENTS$0
M01 · FY2000 · RR
(AMC 011) COL 3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR